Adaptimmune Therapeutics (NASDAQ:ADAP) just reported results for the second quarter of 2024.
- Adaptimmune Therapeutics reported earnings per share of 24 cents. This was above the analyst estimate for EPS of -8 cents.
- The company reported revenue of $128.23 million.
- This was 233.24% better than the analyst estimate for revenue of $38.48 million.